Video

Comparing Two MPN Drugs

Author(s):

Trine Alma Knudsen, M.D.

An expert discusses a trial comparing recombinant interferon alpha-2 with hydroxyurea in patients with myeloproliferative neoplasms (MPNs).

Trine Alma Knudsen, M.D., a Ph.D. student in the department of hematology at the Zealand University Hospital in Roskilde, Denmark, discusses the DALIAH trial, which compared recombinant interferon alpha-2 with hydroxyurea in patients with myeloproliferative neoplasms (MPNs).

Initially, there was a higher percentage of patients in the interferon arm who stopped treatment due to toxicities. However, after about 18 months, the researchers saw that there wasn’t much difference between the two drugs. But according to other studies, Knudsen said, staying on interferon might be worth it, as it may prove to be the superior drug after a longer time on treatment.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Image of two doctors and text.
Image of man.
Image of thumbnail.
Patients can prepare personal overviews to help care teams connect with them as individuals, explained Michelle Kirschner in an interview with CURE.
Enhertu with Perjeta nearly doubled progression-free survival versus standard treatment in metastatic HER2-positive breast cancer, study shows.
Expanding on a New Way to Manage Polycythemia Vera Without Iron Deficiency
Image of woman.
Image of two people.
Image of doctor.
Image of woman.
Related Content
Image of blood cells.
June 11th 2025

Rusfertide Reduces Phlebotomy Need, Improves Quality of Life in Polycythemia Vera

Ryan Scott
Treatment with the investigational therapeutic rusfertide has proven to be a potential treatment option for patients with polycythemia vera.
Cancer Horizons podcast logo
January 8th 2024

FDA Stops Lung Cancer Trial, CAR-T Cell Therapy Is Cost Effective, Novel Drug Slows Fibrosis

Alex Biese Brielle Benyon
The year 2024 is now underway. After a busy 2023, we’re now looking back at some of the oncology headlines from the new year.
blood cells.
May 29th 2025

Pelabresib and Rituxan Combo Improves Outcomes in Myelofibrosis

Ryan Scott
A patient and provider share updates on pelabresib plus Rituxan treatment, which met the MANIFEST-2 trial's primary end point for those with myelofibrosis.
LeVar Burton Helping the MPN Community Through Advocacy and Storytelling
December 16th 2021

LeVar Burton Helping the MPN Community Through Advocacy and Storytelling

Jamie Cesanek Darlene Dobkowski, MA
On this episode of the “Cancer Horizons” podcast, LeVar Burton sits down with CURE® to talk about the importance of MPN awareness and the power of storytelling in advocacy.
Dr. Suresh S. Ramalingam explains that patients with stage 3 lung cancer who undergo chemotherapy and radiation may develop radiation pneumonitis.
May 7th 2025

Managing Lung Inflammation After Chemoradiation and Tagrisso

Dr. Suresh S. Ramalingam
Dr. Suresh S. Ramalingam explains that patients with stage 3 lung cancer who undergo chemotherapy and radiation may develop radiation pneumonitis.
Image of blood cells.
May 6th 2025

Givinostat Wins U.S. FDA Fast Track Designation for Patients With PV

Ryan Scott
Treatment with givinostat has received fast track designation from the United States Food and Drug Administration for patients with polycythemia vera.